X
All Data
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sol-Gel Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2020
Details:
Consistent with Sol-Gel’s prior agreements, Perrigo will seek regulatory approval with the U.S. FDA for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021
Details:
AbbVie received an information request from the FDA for an updated assessment of the benefit-risk profile for upadacitinib in atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
RINVOQ demonstrated significant improvement in skin clearance and reduction in itch in adults and adolescents with moderate to severe atopic dermatitis compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
